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Abstract
Background: The pathological diagnosis of idiopathic interstitial pneumonias (IIP) by surgical lung
biopsy is important for clinical decision-making. However, there is a need to use less invasive
biomarkers to differentiate nonspecific interstitial pneumonia (NSIP) from other IIP such as usual
interstitial pneumonia (UIP). Heat shock protein (HSP) 47, a collagen-specific molecular chaperone,
is involved in the processing and/or secretion of procollagen. HSP47 is increased in various fibrotic
diseases. We investigated the autoantibodies to HSP47 in IIPs.
Methods: We measured the serum levels of the autoantibodies to HSP47 in 38 patients with
various forms of IIP [16 with idiopathic pulmonary fibrosis (IPF), 15 with idiopathic NSIP, 7 with
cryptogenic organizing pneumonia (COP)] and 18 healthy volunteers.
Results: The serum levels of autoantibodies to HSP47 in patients with idiopathic NSIP were
significantly higher than in patients with IPF (P < 0.01), COP (P < 0.05), and healthy volunteers (P
< 0.05). In addition, those in fibrosing NSIP were significantly higher than those of cellular and
fibrosing NSIP (p < 0.05).
Conclusion: We found high levels of anti-HSP47 autoantibody titers in sera of patients with
idiopathic fibrosing NSIP compared with other IIPs and healthy volunteers.
Background
The classification of idiopathic interstitial pneumonias
(IIP) includes seven clinico-radiologic-pathological enti-
ties. Usual interstitial pneumonia (UIP) and nonspecific
interstitial pneumonia (NSIP) are the two largest subsets
of IIP [1,2]. The distinction between NSIP and UIP is
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important for clinical decision-making because the prog-
nosis is generally better and the response to corticoster-
oids and immunosuppressants is also better in patients
with NSIP compared with UIP [3-7]. In addition, patients
with cellular NSIP are reported to have excellent long-
term prognosis, while the majority of patients with
fibrotic NSIP die mostly within 5 to 10 years of diagnosis
[6]. Because of these reasons, the distinction between cel-
lular NSIP and fibrotic NSIP is also important.
Clinicians often speculate on the presence of such patho-
logical changes based on noninvasive imaging studies
such as high-resolution computed tomography (HRCT)
scans. However, the discrimination between NSIP and
UIP cannot always be predicted accurately by HRCT.
Although surgical (open or thoracoscopic) lung biopsy
has been traditionally the ''gold standard'' for the diagno-
sis of interstitial lung diseases (ILD) and is clinically rele-
vant for selection of appropriate therapy [8], it seems to be
relatively invasive examination especially for patients
with advanced ILD. Accordingly, less invasive biomarkers
that distinguish NSIP from other types of IIP should be
developed.
Heat shock protein (HSP) 47 is a collagen-binding, stress-
inducible protein localized in the endoplasmic reticulum
and is never released into the extracellular matrix. HSP47
has a specific role only in the intracellular processing of
procollagen production as a collagen-specific molecular
chaperone [9-12]. HSP47 expression is upregulated in
animals with experimentally-induced fibrosis, including
murine bleomycin-induced pulmonary fibrosis [13,14],
rat peritoneal screlosis [15] and carbon tetrachloride-
induced rat liver cirrhosis [16]. In addition, we reported
previously that there was also increased expression of
human HSP47 in the fibrotic lesions of idiopathic pulmo-
nary fibrosis (IPF) [17,18], fibrotic transplanted kidney
[19], and peritoneal sclerosis [20]. Recent reports have
demonstrated that HSP47 expression is highly tissue- and
cell-specific, restricted to mostly phenotypically altered
collagen-producing cells, and correlates well with that of
collagen [13,17-20]. These findings suggest the important
role of HSP47 in collagen synthesis in various fibrotic dis-
orders.
HSP47 is also identified as an autoantigen in the sera of
several rheumatoid arthritis (RA) patients [21,22]. Higher
levels of HSP47 protein and autoantibodies to HSP47 in
sera were also found in patients with the rheumatic
autoimmune diseases, especially mixed connective tissue
disease (MCTD) [23]. Despite these observations, little is
known about the relationship between fibrotic interstitial
lung diseases and autoantibodies to HSP47.
We hypothesized that autoantibody titers to HSP47 in
sera are different in idiopathic UIP, idiopathic NSIP, COP
and healthy subjects.
Methods
Study populations
The subjects of this study were all the patients admitted to
the hospitals of Nagasaki University School of Medicine
and Oita University Faculty of Medicine from April 1997
to March 2004 in whom the diagnosis of interstitial pneu-
monia was confirmed pathologically, and 18 healthy
adult volunteers. This is a retrospective study. The patients
included 16 patients with IPF (UIP), 15 with idiopathic
NSIP, 7 with cryptogenic organizing pneumonia (COP).
The diagnosis of UIP and NSIP was confirmed pathologi-
cally by open lung biopsy or video-assisted thoracoscopic
surgery (VATS) and classified according to the American
Thoracic Society/European Respiratory Society consensus
criteria [1]. Idiopathic NSIP patients included 7 with cel-
lular and fibrosing pattern and 8 with fibrosing pattern
[1]. The diagnosis of COP was established histopatholog-
ically by VATS in one patient and by transbronchial lung
biopsy in 6 patients. Sera were obtained from these
patients within one month before lung biopsy. Patients
with fibrotic disease in any organ other than pulmonary
fibrosis were excluded from the study, and no fibrotic dis-
ease other than pulmonary fibrosis was detected in any
patient during the study. These patients had neither signs
nor positive serological and other markers of collagen vas-
cular diseases. Patients with cancer in any organ and those
suspected to have malignancy were excluded from the
study. None of these patients had received steroids or
other immunosuppressants at the time of clinical sample
collection. Patients characteristics before lung biopsy
including age, smoking history, results of pulmonary
function tests and arterial blood gas analysis were col-
lected from either the clinical notes or the records of their
general practitioners. Sera were also obtained from 8
healthy male and 10 healthy female volunteers (median
age 31, range 26–60). All healthy volunteers had normal
chest radiographs, were free of symptoms and not taking
any medications. The study protocol was approved by the
institutional review board, and informed consent was
obtained from the patients and healthy volunteers.
Determination of autoantibody titers by ELISA
Enzyme-linked immunosorbent assay (ELISA) for deter-
mination of autoantibodies to HSP47 was carried out
essentially as described previously [23,24]. Briefly, recom-
binant HSP47 protein diluted at 1 μg / m l  i n  5 0  m M
sodium carbonate buffer (pH 9.6) was immobilized on a
96-well microplate. The wells were blocked with 2%
bovine serum albumin (BSA) in phosphate-buffered
saline (PBS) and then incubated with human sera diluted
100-fold. Specific binding of serum IgG to HSP47 wasBMC Pulmonary Medicine 2008, 8:23 http://www.biomedcentral.com/1471-2466/8/23
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detected by subsequent incubation of horseradish peroxi-
dase-conjugated goat antibodies specific for the γ-chain of
human IgG (BioSource, Camarillo, CA) and 3,3',5,5'-
tetramethylbenzidine solution. After terminating the reac-
tion with equal volume of 1 M phosphoric acid, absorb-
ance at 450 nm was measured and used as an antibody
titer.
Statistical analysis
All values were expressed as median (range). Differences
among groups were examined using Kruskal-Wallis test.
The post-hoc test used was Scheffe test. Statistical analysis
was performed using StatView-J 5.0 software (Abacus
Concepts; Berkeley, CA). A p value < 0.05 denoted the
presence of a statistically significant difference.
Results
Patient characteristics
Table 1 shows the characteristics of patients enrolled in
this study. The baseline demographic and physiologic
characteristics were similar among the groups.
Anti-HSP47 autoantibody titers in human sera
HSP47-reactive IgG titers of patients with idiopathic NSIP
(median, 0.281 [range, 0.194–0.734]) were significantly
higher than those of idiopathic UIP (0.165 [0.059–
0.361]) (P < 0.01), COP (0.137 [0.101–0.394]) (P <
0.05), and healthy volunteers (0.181 [0.062–0.349]) (P <
0.05) (Fig. 1). HSP47-reactive IgG titers of patients with
fibrosing NSIP (0.367 [0.206–0.734]) were significantly
higher than those of the cellular and fibrosing NSIP
(0.231 [0.194–0.395]) (P < 0.05) (Fig. 2). HSP47-reactive
IgG titers of patients with cellular and fibrosing NSIP,
UIP, COP and healthy controls were not significantly dif-
ferent.
Correlation between anti-HSP47 autoantibody titers in 
sera and clinical course and other markers
Anti-HSP47 autoantibody titers did not correlate with sur-
vival or clinical data such as results of pulmonary function
tests and arterial blood gas analysis (data not shown).
Antibody titers to HSP47 also did not correlate with the
serum levels of KL-6, surfactant protein (SP)-D and SP-A
(data not shown).
Discussion
The present study of biopsy-proven cases clearly demon-
strated that the anti-HSP47 titers of patients with idio-
pathic fibrosing NSIP were higher than those of patients
with idiopathic UIP, idiopathic cellular and fibrosing
NSIP, COP and healthy subjects. In contrast, the anti-
HSP47 autoantibody titers in sera of patients with idio-
pathic UIP and healthy controls were not different despite
the fact that overexpression of HSP47 has been reported
in fibrotic lesions of IPF patients [17,18].
Our results suggest that anti-HSP47 autoantibody titers in
sera might be useful to discriminate between idiopathic
fibrosing NSIP and other types of IIP such as IPF. How-
ever, we do not recommend the use of this serum marker
alone to differentiate idiopathic fibrosing NSIP and other
types of IIP because (1) our study only included a rela-
tively small number of patients, (2) there was some over-
lap in the serum levels of anti-HSP47 autoantibodies
between UIP and NSIP, (3) this is a retrospective study.
Moreover, the patients groups might not represent general
Table 1: Patient characteristics
COP Idiopathic UIP Idiopathic cellular and fibrosing NSIP Idiopathic fibrosing NSIP p value
Age (years) 68 (43–79) 64 (34–75) 71 (56–75) 50 (28–67) ns
Sex (male/female) 5/2 11/5 2/5 4/4 ns
Smoking (none/ex/smoker) 3/3/1 6/4/6 5/1/1 4/2/2 ns
Spirometry:
VC (L) 2.79 (1.86–4.21) 2.73 (1.14–3.60) 2.44 (1.28–3.32) 2.72 (1.73–3.39) ns
predicted VC (%) 101.6 (53.0–111.2) 82.9 (43.3–112.5) 76.6 (56.8–108.1) 94.7 (66.9–101.5) ns
FEV1 (L) 2.17 (1.39–2.81) 2.18 (1.04–2.67) 1.73 (0.99–2.53) 2.2 (1.26–2.98) ns
predicted FEV (%) 77.6 (69.8–80.0) 83.3 (69.4–98.2) 85.0 (60.1–96.2) 80.9 (66.5–89.5) ns
Gas exchange:
DLco (ml/min/mmHg) 10.28 (6.39–17.81) 8.59 (2.32–14.65) 9.94 (7.24–14.60) 12.18 (7.77–19.85) ns
predicted DLco (%) 58.6 (49.3–105.1) 46.3 (14.2–97.3) 67.5 (44.7–109.3) 53.1 (46.8–71.9) ns
Lung volume:
predicted TLC (%) 88.3 (49.0–98.4) 69.3 (32.6–78.7) 68.3 (66.3–104.2) 74.8 (62.9–96.6) ns
TLC (L) 3.41 (2.32–5.81) 3.86 (1.27–4.78) 4.24 (2.27–8.80) 3.15 (2.44–4.46) ns
Arterial blood gases:
PaO2 (mmHg) 76.2 (61.3–83.1) 80.7 (47.2–103.3) 74.2 (70.0–86.4) 85.4 (77.5–92.9) ns
Data are median (range). ns = not significant
COP = cryptogenic organizing pneumonia; DLco = diffusing capacity for carbon monoxide; FEV = forced expiratory volume; NSIP = nonspecific 
interstitial pneumonia; TLC = total lung capacity; UIP = usual interstitial pneumonia; VC = vital capacity.BMC Pulmonary Medicine 2008, 8:23 http://www.biomedcentral.com/1471-2466/8/23
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patient population with IIP because the diagnosis of UIP
and NSIP was confirmed pathologically by open lung
biopsy or video-assisted thoracoscopic surgery and
patients diagnosed only clinically were excluded.
Although surgical lung biopsy has been traditionally the
"gold standard" for the diagnosis of ILD, it seems to be rel-
atively invasive examination especially for patients with
advanced ILD. Accordingly, the study population may
represent only "early and moderate" stage of ILD. Well-
planned prospective study using a large number of
patients are required to determine the cutoff levels of anti-
HSP47 autoantibody titers necessary for the diagnosis,
together with analysis of the sensitivity and specificity of
such levels.
In the present study, we also investigated whether serum
titers of anti-HSP47 autoantibody correlated with clinical
course and other serum markers. However, anti-HSP47
autoantibody titers did not correlate with survival or clin-
ical data such as results of pulmonary function tests and
arterial blood gas analysis (data not shown). This is prob-
ably because of the small sample size. In addition, the titer
of HSP47 antibody did not correlate significantly with the
serum levels of KL-6, SP-D and SP-A, which were previ-
ously reported to be correlated with clinical activity of
interstitial pneumonia [25-27], probably because of dif-
ferences in the origins of these markers.
Why were the serum levels of autoantibody to HSP47 ele-
vated in idiopathic NSIP patients, but not in idiopathic
UIP patients, while fibrotic changes and expression of
HSP47 in the lungs of patients with idiopathic UIP are
much more severe than those with NSIP [18]? HSP47 is
usually never released into the extracellular matrix, so it
appears that intracellular HSP47 protein leaks into the
peripheral blood when there is inflammation leading to
tissue destruction. Elevation of anti-HSP47 autoantibody
titers in idiopathic fibrosing NSIP patients might be due
to the distinctive characteristics of idiopathic fibrosing
NSIP including a variable degree of inflammation and
fibrosis within the alveolar walls, which may induce leak-
age of HSP47 protein into the peripheral blood and sub-
sequently induce the production of anti-HSP47
autoantibody. In contrast, severe fibrosis is seen but
inflammation is mild in idiopathic UIP. A previous report
reported that MCTD patients had markedly high levels of
both HSP47 protein and autoantibodies to HSP47 in the
sera compared with other rheumatic autoimmune dis-
eases, including rheumatoid arthritis, systemic lupus ery-
thematosus, and Sjögren syndrome [23]. This also
suggests that the combination of inflammation and fibro-
sis is necessary for HSP47 protein to leak into the periph-
eral blood. However, this theory does not account for the
reason why HSP47-reactive IgG titers of patients with
fibrosing NSIP were significantly higher than those of idi-
opathic cellular and fibrosing NSIP. Many of the patients
with idiopathic NSIP develop collagen vascular disease
later on in the disease course. The fact that the serum lev-
els of autoantibodies to HSP47 in patients with idiopathic
NSIP were significantly higher than in patients with other
IIPs suggests that the patients with so called "idiopathic"
NSIP might display signs of auto-immunity in contrast to
patients with idiopathic UIP.
As we previously reported, expression of HSP47 was noted
in fibroblasts, myofibroblasts and type II pneumocytes in
idiopathic interstitial pneumonia [17,18]. The expression
level of HSP47 in type II pneumocytes of idiopathic UIP
was significantly higher than that in idiopathic NSIP [18].
In contrast to that, in this study, we demonstrated that the
anti-HSP47 titers of patients with idiopathic NSIP were
significantly higher than those of patients with idiopathic
UIP. We speculate that HSP47 autoantibody might neu-
tralize the HSP47 antigen and suppress the fibrosis in idi-
opathic NSIP. However, there is no direct evidence.
Further studies are warranted in order to elucidate the pre-
cise mechanisms.
Nevertheless, our findings support the concept that these
diseases are different pathophysiological entities with dif-
ferent fibrotic pathways. We speculate that evaluation of
anti-HSP47 autoantibody titers might be a useful method
Scattergram of IgG titers to HSP47 in patients with cryp- togenic organizing pneumonia (COP), idiopathic usual inter- stitial pneumonia (UIP), idiopathic nonspecific interstitial  pneumonia (NSIP) and healthy volunteer Figure 1
Scattergram of IgG titers to HSP47 in patients with 
cryptogenic organizing pneumonia (COP), idiopathic 
usual interstitial pneumonia (UIP), idiopathic non-
specific interstitial pneumonia (NSIP) and healthy 
volunteer. Antibody titers are expressed as absorbance at 
450 nm.
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to understand the differences in the underlying patho-
genic mechanisms of these diseases.
Conclusion
In conclusion, we found high levels of anti-HSP47
autoantibody titers in sera of patients with idiopathic
fibrosing NSIP compared with idiopathic UIP, idiopathic
cellular and fibrosing NSIP, COP and healthy volunteers.
However, further studies of a large number of patients are
required to determine the prognostic and therapeutic val-
ues of anti-HSP47 autoantibody titers.
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